Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Accumulated Expenses (2023 - 2026)

BioAge Labs' Accumulated Expenses history spans 3 years, with the latest figure at $4.4 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 62.96% to $4.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.4 million, a 62.96% decrease, with the full-year FY2025 number at $4.4 million, down 62.96% from a year prior.
  • Accumulated Expenses hit $4.4 million in Q4 2025 for BioAge Labs, down from $7.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for BIOA hit a ceiling of $11.8 million in Q4 2024 and a floor of $2.3 million in Q2 2025.
  • Historically, Accumulated Expenses has averaged $7.0 million across 3 years, with a median of $7.3 million in 2025.
  • Biggest five-year swings in Accumulated Expenses: surged 48.03% in 2024 and later plummeted 62.96% in 2025.
  • Tracing BIOA's Accumulated Expenses over 3 years: stood at $7.9 million in 2023, then skyrocketed by 48.03% to $11.8 million in 2024, then crashed by 62.96% to $4.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for BIOA at $4.4 million in Q4 2025, $7.3 million in Q3 2025, and $2.3 million in Q2 2025.